The American Society of Clinical Oncology (ASCO) previously published evidencebased
guidelines for the treatment of unresectable non–small-cell lung cancer (NSCLC)[1]. ASCO …

This special supplement to The Journal of Nuclear Medicine is a detailed tabulation of
literature on FDG PET in oncology (1993–June 2000), cardiology (1986–June 2000), and …

ContextFocal pulmonary lesions are commonly encountered in clinical practice, and
positron emission tomography (PET) with the glucose analog 18-fluorodeoxyglucose (FDG) …

Purpose: To compare the diagnostic accuracy of computed tomography (CT) and positron
emission tomography (PET) with 18-fluorodeoxyglucose (FDG) for mediastinal staging in …

Positron emission tomography (PET) is the most powerful molecular imaging technique
currently available for clinical use. Because deranged tumour metabolism is a common …

Lung cancer is the cause of 32% of all male cancer deaths and 25% of all female cancer
deaths. Because the prognosis depends on early diagnosis and staging, continuous …

Objectives To evaluate the predictive accuracy as well as the rates of false-positive and false-
negative results of CT and positron emission tomography (PET)-fluorodeoxyglucose (FDG) …

Background. Positron emission tomography imaging is gaining popularity as a noninvasive
staging tool in non-small cell lung cancer. Nonmalignant processes can also affect radio …

Lung cancer is the leading cause of cancer-related death in industrialized countries. The
overall mortality rate for lung cancer is high, and early diagnosis provides the best chance …

Purpose: To report a retrospective study concerning the impact of fused 18F-fluoro-deoxy-d-
glucose (FDG)-hybrid positron emission tomography (PET) and CT images on three …